ALC— AI Stock Forecast & Price Targets
Published 7/2/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live ALC price forecast →
ALC faces near-term pressure from Asia-Pacific softness and margin compression but shows resilience in core surgical segments with strong cash flow. The forecast band suggests potential upside toward $88.21 target, though valuation remains elevated at 40x trailing P/E versus forward growth of 13.65% over five years.
Hold near $66.82; invalidation if price breaks below $63.00 support level or fails to close above $70.00 resistance within 4 weeks
Target $88.21 by Q4 2026 based on forecast band and surgical growth, but monitor Asia-Pacific recovery and margin pressure; catalysts include FDA approvals for new products and tariff relief
Terminal value driven by premium lens adoption in emerging markets and refractive surgery expansion, though secular risks from digital alternatives could limit upside to $95.00
Revenue grew 7.14% YoY (Q1 2026), but margins compressed to 7.70% TTM from 9.06% in prior periods due to tariffs and competition. Balance sheet shows strong liquidity ($3.40/share cash) with low debt-to-equity (0.24x), though high leverage (debt/equity 23.77x) is a concern. Free cash flow of $1.23B supports dividends at 0.54% yield, but weak ROE (3.71%) and declining EPS growth (-26.32% YoY TTM) indicate quality concerns. The forecast band's $88.21 target implies a 32% upside from current price, yet valuation remains elevated at 40x trailing P/E versus forward P/E of 16.83.
The chart shows green actual price trending below the yellow forecast band (77.148-77.157), with recent support at $66.82 and resistance near $77.15. The model's directional accuracy is only 66% for 1-day forecasts, suggesting high noise in short-term moves. However, the forecast band implies a potential breakout toward $88.21 target, though current price is below the 200-day SMA (-11.59%) and RSI (49.16) suggests neutral momentum.
Recent Zacks articles highlight Asia-Pacific softness and recall costs as key risks, but Q1 2026 revenue growth of 6% in Surgical/Vision Care units provides a counterbalance. The $88.21 target price from market snapshot aligns with the forecast band's upper limit, though macro pressures (tariffs, competition) could delay recovery. Social sentiment shows 71% bullishness, but retail positioning is noisy and not indicative of fundamental strength.
- Premium lens growth (MyDay) supported by Asia-Pacific momentum despite softness
- Refractive surgery products like WaveLight showing strong adoption rates
- Asia-Pacific tariff pressures reducing margins
- Fierce competition in surgical segment eroding pricing power
- Valuation at 40x trailing P/E vs. forward growth of 13.65% over five years
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord